BHC AI Analysis Overview
Keys for Bullish View
- Value≥4
- Dividend≥2
Analysis Conclusion
The stock has a low value rating. If your investment strategy is value-oriented and you have long-term positions, it's crucial to adhere to your exit plan and consider reducing holdings.
BHC Current Performance
1.87%
Bausch health companies inc
1.19%
Avg of Sector
1.11%
S&P500
Top 10 High Relevance to BHC
| Symbol | Company Name | Value | Trend | Swing Trading | Whale Interest | Dividend | Add to Watchlist |
|---|---|---|---|---|---|---|---|
VIRX | Viracta therapeutics inc | 3 | 1 | 2 | 1 | 1 | |
SVRA | Savara inc | 2 | 3 | 2 | 3 | 1 | |
ENVB | Enveric biosciences inc | 3 | 2 | 3 | 1 | 1 | |
CLRB | Cellectar biosciences inc | 2 | 2 | 2 | 2 | 1 | |
IMCC | Im cannabis corp | 2 | 2 | 2 | - | 1 |
- VIRX Viracta therapeutics incValue 3Trend 1Swing Trading 2Whale Interest 1Dividend 1See more
BHC Profile
Bausch Health Companies Inc. is a global diversified pharmaceutical company. The Company develops, manufactures, and markets a range of products primarily in gastroenterology (GI), hepatology, neurology, dermatology, eye health, and others, through Bausch + Lomb Corporation. Its Salix segment consists of sales in the United States of GI products. Its International segment consists of sales, with the exception of sales of Bausch + Lomb products and Solta Medical aesthetic medical devices, outside the United States and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products and other products. Its Solta Medical segment consists of global sales of Solta Medical aesthetic medical devices. Its Diversified segment consists of sales in the United States of pharmaceutical products in the areas of neurology and certain other therapeutic classes. Its Bausch + Lomb segment consists of global sales of Bausch + Lomb Vision Care, surgical and pharmaceutical products.